Health
Medical Devices
Biotechnology

Emergent BioSolutions

$48.33
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.67 (-1.37%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell EBS and other stocks, options, ETFs, and crypto commission-free!

About

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers specialty products for civilian and military populations that address accidental, intentional and naturally occurring public health threats. Read More Its business units include Vaccines and Anti-Infectives; Antibody Therapeutics; Devices; and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri in May 1998 and is headquartered in Gaithersburg, MD.

Employees
1,705
Headquarters
Gaithersburg, Maryland
Founded
1998
Market Cap
2.47B
Price-Earnings Ratio
39.59
Dividend Yield
0.00
Average Volume
379.78K
High Today
$49.90
Low Today
$48.25
Open Price
$48.92
Volume
291.59K
52 Week High
$73.89
52 Week Low
$46.93

Collections

Health
Medical Devices
Biotechnology
Biopharmaceutical
Pharmaceutical
Manufacturing
Health And Wellness
Therapy

News

Yahoo FinanceMar 23

Emergent Biosolutions (EBS) Down 24.2% Since Last Earnings Report: Can It Rebound?

Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. It has been about a month since the last earnings report for Emergent Biosolutions (EBS). Shares have lost about 24.2% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Emergent Biosolutions due for a breakout? Before we dive into how investors and analysts have reacted as of late, le...

19
TradingNewsNowMar 21

Present Movement: Emergent Biosolutions (NYSE: EBS)

Emergent Biosolutions trades as part of the biotechnology industry and is part of the healthcare sector. The company CEO is Daniel J. Abdun-Nabi. Emergent BioSolutions Inc is a biotechnology company operating in two divisions: biodefense and biosciences. The company focuses on countermeasures that address public health threats around hematology and oncology therapeutics. Previous Intraday Trading Performance: The EBS stock showed a previous change of -1.81% with an open at 48.86 and a close of 48.23. It r...

49
Yahoo FinanceMar 20

Emergent Begins Phase III Study on Anthrax Vaccine AV7909

Emergent BioSolutions Inc. EBS announced that it has initiated a phase III study to evaluate AV7909 for the post-exposure prophylaxis of anthrax disease. The phase III program will evaluate the lot consistency, immunogenicity and safety of AV7909 (anthrax vaccine adsorbed with CPG 7909 adjuvant) following a two-dose schedule, administered intramuscularly in healthy adult patients. AV7909 is currently being developed for post-exposure prophylaxis of anthrax disease, resulting from a suspected Bacillus anthr...

28

Earnings

-$0.03
$0.34
$0.70
$1.07
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 2, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.